The global vitiligo treatment market was estimated to be worth USD 1.42 billion in 2021. The market is likely to grow at a rate of 5.6% in the forecast period of 2023-2031. Driven by the growing demand and increasing R&D activities, the market is anticipated to be worth USD 2.32 billion by 2030.
Vitiligo is a skin disorder affecting the original colour of the skin and causing discolouration or fading of the skin colour. Vitiligo is characterised by the formation of macules, patches that are less than or more than 5mm in size.
Vitiligo is mainly caused by the deficiency of melanocytes due to the self-attack by the immune system on its melanocytes. The less production of melanocytes leads to the lower production of the pigment melanin, which is responsible for giving skin colour.
With time, the progression of vitiligo increases, starting from small patches on fewer body parts to larger patches or other parts of the body. Vitiligo generally starts from the hands, legs, palms, feet, and face, but eventually may spread to mucous membranes, eyes and inner ears.
Based on the concentration and affected area, vitiligo is of several types including generalised, segmental, mucosal, focal, trichome, and universal. Vitiligo affects nearly 1% of the population or more across the world and is prevalent equally in people of all genders and races.
Vitiligo is expected to be caused by certain genetic and neurogenic factors, that are toxic to melanocytes and thus can lead to vitiligo. Vitiligo is generally diagnosed with the help of white patches that are visible on the skin. A test based on ultraviolet light is also used to examine and differentiate normal skin from the other affected parts.
Vitiligo is treated using a combination of several therapies that aim at restoring the original skin colour or eliminating the remaining colour to maintain the uniformity of skin colour.
The vitiligo treatment market can be categorised into the following segments:
Market Breakup by Treatment Type
Market Breakup by Indication Type
Market Breakup by End User
Market Breakup by Route of Administration
Market Breakup by Region
The vitiligo treatment market is primarily driven by the increasing patient pool and rising disease burden. According to the American Academy of Dermatology, nearly one in four Americans suffer from vitiligo, this has stimulated the demand for advanced and effective therapeutic options that are expected to increase market growth. Further, raising awareness among the general population has also led to market growth in developed and developing nations.
With the increasing demand, the key players and major pharmaceutical companies have shifted their focus toward the development of novel therapeutic agents. The growing research and developmental activities and the increasing investments in this sector have also propelled the market growth during the forecast period. For example, Incyte, a key market player is conducting clinical trials for testing the safety and efficacy of ruxolitinib cream for the management of vitiligo.
The vitiligo treatment market revenue growth is driven by technological advancements, and increasing adoption of advanced therapeutics by hospitals, surgical centres, and ambulatory care centres are expected to boost the market growth. Additionally, the rising demand for precision medicine and higher adoption of point-of-care diagnostics and home care settings are expected to augment the market revenue growth during the forecast period.
North America is anticipated to hold the largest share of the vitiligo treatment market owing to the rising disease prevalence, the discovery of advanced diagnostics and therapeutics, and the significant presence of many key players in that region.
The Asia Pacific is expected to witness the fastest growth during the forecast period due to increasing awareness, emerging treatment options, growing research and development activities and favouring government initiatives in the developing nations.
There is no approved treatment regimen for the management of vitiligo, and tremendous research and developmental activities are being conducted for the discovery of novel therapeutic agents for better therapeutic efficacy. The treatment involves different medications, several therapies, and various surgical procedures.
The type of treatment depends on the age of the patient, the affected area, and the speed of the disease progression. The treatments are based on repigmentation and depigmentation. The medications used are topical corticosteroids and topical calcineurin inhibitors such as pimecrolimus and tacrolimus. These drugs have exhibited beneficial effects in the treatment of the affected skin in the early stages of vitiligo.
Several therapies, such as light therapy have been effective in lowering or stopping the disease progression. The combination of light therapy with other medications has been found effective in vitiligo treatment. Corticosteroids or psoralen are combined with light therapy to return the original skin colour and thus help in the treatment of vitiligo.
Surgical interventions are used for the treatment in case of medications or therapy failure. Skin grafting, blister grafting, and cellular suspension transplant are the commonly used surgeries utilised for restoring the lost colour.
In skin grafting, the patches of healthy skin colour are grafted to the affected parts to manage the vitiligo progression. Blister grafting is another surgical procedure to create blisters on the pigmented skin through suction. Cellular suspension transplant is a repigmentation procedure to transplant chemically treated cells onto the affected area.
With extensive research and development, scientists are effortlessly working on developing novel therapeutic agents that could help in the treatment of vitiligo. Many drugs are being discovered and under different phases of clinical trials for assessing their safety, efficacy, tolerability, and pharmacokinetics.
Novel therapeutic agents acting against Janus-activated kinases (JAKs) have been proven for the treatment of vitiligo. Many drugs possessing the JAK inhibition mechanism are under clinical trials and are expected to provide therapeutic efficacy in the management of vitiligo.
Baricitinib, a novel JAK1 and JAK2 inhibitor, is under Phase II clinical trials and has shown promising results in the vitiligo treatment in combination with phototherapy. Ifidancitinib, another investigational drug, is tested and possesses JAK1 and JAK3 inhibition properties. Combination therapy of brepocitinib and ritlecitinib is being evaluated in clinical testing and is a JAK3 and tyrosine kinase inhibitor.
Incyte Corporation, a key market player, has discovered a novel therapeutic agent, auremolimab, an anti-monoclonal antibody and is expected to enter clinical development by 2023. This drug acts against the memory T cells that have shown efficacy in the vitiligo treatment.
The United States Food and Drug Administration has recently approved a novel medication, Opezelura cream for the treatment of non-segmental vitiligo. This topical agent has become the first approved treatment for repigmentation in patients and possesses JAK inhibition activity.
Avita Medical, a major company, is conducting clinical trials for the RECELL system, which has demonstrated positive clinical trial results for the treatment of stable vitiligo.
All the discovered treatment approaches are based on the aim of repigmentation and subsequently will help in treating vitiligo. Several ongoing clinical trials are emerging as key trends which are likely to bolster the growth of the market.
The report gives an in-depth analysis of the key players involved in the vitiligo treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Treatment Type||
|Breakup by Indication Type||
|Breakup by End User||
|Breakup by Route of Administration||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Vitiligo Overview
4.1 Guidelines and Stages
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
22.214.171.124 Patent Status and Expiry
126.96.36.199 Timelines from Drug Development to Commercial Launch
188.8.131.52 New Drug Application
184.108.40.206.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
220.127.116.11 US FDA
18.104.22.168 EU EMA
22.214.171.124 INDIA CDSCO
126.96.36.199 JAPAN PMDA
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Vitiligo Treatment Market
8.1 Global Vitiligo Treatment Market Overview
8.2 Global Vitiligo Treatment Market Analysis
8.2.1 Market Overview
188.8.131.52 Global Vitiligo Treatment Market Historical Value (2016-2022)
184.108.40.206 Global Vitiligo Treatment Market Forecast Value (2023-2031)
8.2.2 Global Vitiligo Treatment Market by Treatment Type
220.127.116.11 Market Overview
18.104.22.168.1.1 Calcineurin Inhibitor
22.214.171.124.2.2 Light Therapy
126.96.36.199.3.1 Skin Grafting
188.8.131.52.3.2 Blister Grafting
184.108.40.206.3.3 Micro Pigmentation
8.2.3 Global Vitiligo Treatment Market by Indication Type
220.127.116.11 Market Overview
18.104.22.168.1 Nonsegmental Vitiligo
22.214.171.124.2 Segmental Vitiligo
8.2.4 Global Vitiligo Treatment Market by End User
126.96.36.199 Market Overview
188.8.131.52.2 Aesthetic Clinics
8.2.5 Global Vitiligo Treatment Market by Route of Administration
184.108.40.206 Market Overview
8.2.6 Global Vitiligo Treatment Market by Region
220.127.116.11 Market Overview
18.104.22.168.1 North America
22.214.171.124.3 Asia Pacific
126.96.36.199.4 Middle East and Africa
188.8.131.52.5 Latin America
9 North America Vitiligo Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Vitiligo Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
11 Asia Pacific Vitiligo Treatment Market
11.1 Market Share by Country
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
12 Latin America Vitiligo Treatment Market
12.1 Market Share by Country
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
13 Middle East and Africa Vitiligo Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
14 Global Vitiligo Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Dermavant Sciences, Inc. (Roivant Sciences Ltd.)
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.3 Aclaris Therapeutics, Inc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.4 Dr. Reddy’s Laboratories Ltd.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.5 GSK plc
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.6 Bristol-Myers Squibb Company
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.7 Clinuvel Pharmaceuticals Ltd
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.8 Applied Biological Laboratories
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.9 Boston Pharmaceuticals
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.10 F. Hoffmann-La Roche Ltd
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.11 Pfizer Inc.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
16 Global Vitiligo Treatment Market Distribution Model (Additional Insight)
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
*Additional insights provided are customizable as per client requirements.
The market is primarily driven by the rising prevalence of vitiligo and other dermatological disorders, increasing research and developmental activities and novel product launches and approvals, and favouring government initiatives.
The different regions in the market are North America, Europe, Asia Pacific, Latin America and the Middle East and Africa.
North America is anticipated to hold the largest share of the market during the forecast period.
Based on the treatment type, the market is segmented into medications, therapy, and surgery, among others.
Based on the indication type, the market is bifurcated into segmental vitiligo and nonsegmental vitiligo, among others.
Based on the end users, the market is divided into hospitals and aesthetic clinics, among others.
Based on the route of administration, the market is categorised into oral, parenteral, and topical, among others.
The key companies involved in the market are Dermavant Sciences, Inc. (Roivant Sciences Ltd.), Incyte, Aclaris Therapeutics, Inc., Dr Reddy’s Laboratories Ltd., GSK plc, Bristol-Myers Squibb Company, Clinuvel Pharmaceuticals Ltd, Applied Biological Laboratories, Boston Pharmaceuticals, F. Hoffmann-La Roche Ltd, and Pfizer Inc., among others.
Single User License
Five User License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.